文献速递血栓与止血

可溶性纤维蛋白导致获得性血小板糖蛋白VI信号缺陷:对凝血病的意义

Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.
PubMed 文献 · J Thromb Haemost · 2017-10-27

研究探讨凝血病血液中循环凝血酶通过可溶性纤维蛋白生成导致血小板糖蛋白VI(GPVI)信号缺陷的机制;在阿哌沙班处理的血小板富血浆中,凝血酶(1-10 nM)暴露而非ADP或U46619可阻断后续GPVI激活,该效应依赖可溶性纤维蛋白多聚化,GPRP或T101可阻断,且全血微流控中血小板沉积减少>50%。

要点

  • 凝血酶(1-10 nM)暴露可阻断后续GPVI激活,该效应不被PAR-1/4激动肽模拟。
  • 可溶性纤维蛋白多聚化是GPVI信号缺陷的关键,GPRP或T101可阻断。
  • 凝血病血液中仅1%纤维蛋白原转化即可产生90 nM可溶性纤维蛋白,远超GPVI约1 nM。

核心结论

  • 可溶性纤维蛋白而非凝血酶经PAR-1和PAR-4激活血小板,下调GPVI信号,可能导致内源性或输注血小板后续功能低下。

研究设计与样本

  • 体外研究,使用钙染料负载的血小板、阿哌沙班处理的血小板富血浆(12% PRP)、洗涤血小板及全血微流控实验。

主要发现

  • 阿哌沙班处理的血小板富血浆(12% PRP)暴露于凝血酶(1-10 nM)而非ADP或血栓素模拟物U46619,显著阻断后续由convulxin、胶原相关肽或纤维状胶原引起的GPVI激活。
  • 对convulxin不敏感性的出现需要200-500秒的凝血酶暴露,不被PAR-1/4激活肽模拟,洗涤血小板中未观察到,且被纤维蛋白聚合抑制剂GPRP或因子XIIIa抑制剂T101阻断。
  • 沃拉帕沙阻断凝血酶诱导的钙动员但对凝血酶损害GPVI信号无影响;GM6001或GR144053不影响convulxin不敏感性。
  • 洗涤血小板重悬于纯化纤维蛋白原后经凝血酶处理也产生convulxin不敏感性,GPRP可预防。
  • 阿哌沙班/PPACK处理的全血暴露于凝血酶处理的纤维蛋白原后,在胶原微流控实验中血小板沉积减少>50%,且需要可溶性纤维蛋白组装。

关键数值与推荐

  • 凝血病血液中仅1%血浆纤维蛋白原转化即可产生90 nM可溶性纤维蛋白,远超血液中约1 nM的GPVI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Collagen and thrombin when used simultaneously generate highly activated platelets. The effect of thrombin stimulation on subsequent glycoprotein VI (GPVI) function was observed. Soluble fibrin, but not protease activated receptor (PAR) activation, prevented GPVI activation. Circulating soluble fibrin in coagulopathic blood may cause an acquired GPVI signaling defect. SUMMARY: Background In coagulopathic blood, circulating thrombin may drive platelet dysfunction. Methods/Results Using calcium dye-loaded platelets, the effect of thrombin exposure and soluble fibrin generation on subsequent platelet GPVI function was investigated. Exposure of apixaban-treated platelet-rich plasma (12% PRP) to thrombin (1-10 nm), but not ADP or thromboxane mimetic U46619 exposure, dramatically blocked subsequent GPVI activation by convulxin, collagen-related peptide or fibrillar collagen. Consistent with soluble fibrin multimerizing and binding GPVI, the onset of convulxin insensitivity required 200-500 s of thrombin exposure, was not mimicked by exposure to PAR-1/4 activating peptides, was not observed with washed platelets, and was blocked by fibrin polymerization inhibitor (GPRP) or factor XIIIa inhibitor (T101). PAR-1 signaling through Gαq was not required because vorapaxar blocked thrombin-induced calcium mobilization but had no effect on the ability of thrombin to impair GPVI-signaling. Convulxin insensitivity was unaffected by the metalloprotease inhibitor GM6001 or the αIIb β3 antagonist GR144053, indicating negligible roles for GPVI shedding or αIIb β3 binding of fibrin. Thrombin treatment of washed platelets resuspended in purified fibrinogen also produced convulxin insensitivity that was prevented by GPRP. Exposure of apixaban/PPACK-treated whole blood to thrombin-treated fibrinogen resulted in > 50% decrease in platelet deposition in a collagen microfluidic assay that required soluble fibrin assembly. Conclusions Conversion of only 1% plasma fibrinogen in coagulopathic blood would generate 90 nm soluble fibrin, far exceeding ~1 nmGPVI in blood. Soluble fibrin, rather than thrombin-induced platelet activation throuh PAR-1 and PAR-4, downregulated GPVI-signaling in response to stimuli, and may lead to subsequent hypofunction of endogenous or transfused platelets.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lee MY, Verni CC, Herbig BA, et al. Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy. J Thromb Haemost. 2017. PMID: 28981200. doi:10.1111/jth.13863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。